However, the general experience with AR inhibitors in a randomized double-blind study of patients with insulin-dependent diabetes (IDDM), either with sorbinil or placebo, was found to be disappointing as no significant differences were noted between the treatment and placebo groups. The gene discussed is AR; the disease is type 1 diabetes mellitus.